Virax Biolabs Group Limited

US$0.79As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:VRAXHealthcare
Country USA
PE (Fwd) •••
TSR 4Y CAGR (82.47%)
Div yield —
ROE (78.65%)
Biotechnology
Beta (5Y) 1.48
PE TTM —
TSR TTM (94.36%)
Mkt cap US$0.631M
ROIC (58.87%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.992
25.21%
113.39%
Hold 12|8|9|2|8
3Q26
4Q26
1Q27
2Q27
Earnings per share$
0.01
0.01
0.01
0.01
25.41%
17.40%
5.31%
(4.46%)
Revenue$M
0.034
0.035
0.036
0.036
6.06%
9.95%
8.80%
13.45%
Peers (US$0.631M)
Cap (US$)
PE
2.468M
—
2.387M
—
Capital
TTM
5Y
10Y
Leveragex
0.885
0.488
0.359
EBIT/Intx
0.827
0.849
0.757
Own earn%
(53.24)
74.20
49.60
Sh yield%
41.44
35.11
32.05
Owners
Insiders/Inst%
10.67
47.62
Short interest%
0.91
SBC / revenue%
1.55
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
5–19
$1 testx
—
Incr. ROIC%
4